Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAKTI-1: AUR107 in Relapsed Advanced Malignancies
NCT05865002Phase 1Recruiting
- Sponsor
- Aurigene Pharmaceutical Services Limited
- Start
- Sep 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AUR-107 in solid tumor, sponsored by Aurigene Pharmaceutical Services Limited. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events at 28 days and 6 more. Started Sep 2023; status: recruiting.
02
Drugs
AUR-107
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05865002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05865002.